$0.6796
0.0096[1.43%]
At close: Apr 22
$0.6796
0[0.00%]
After Hours: 9:29AM EDT
Chemomab Therapeutics
(NASDAQ:CMMB)Chemomab Therapeutics Stock (NASDAQ:CMMB), Analyst Ratings, Price Targets, Predictions
Chemomab Therapeutics Ltd has a consensus price target of $20.5, established from looking at the 9 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Roth MKM, and Roth MKM on March 8, 2024, December 19, 2023, and October 6, 2023. With an average price target of $4.67 between Oppenheimer, Roth MKM, and Roth MKM, there's an implied 586.68% upside for Chemomab Therapeutics Ltd from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Roth MKM
Aegis Capital
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Chemomab Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/08/2024 | CMMB | Buy Now | Chemomab Therapeutics | $0.68 | — | Oppenheimer | Jeff Jones | — | Maintains | Perform | Get Alert |
| 12/19/2023 | CMMB | Buy Now | Chemomab Therapeutics | $0.68 | 930.02% | Roth MKM | Dylan Dupuis | $7 → $7 | Reinstates | → Buy | Get Alert |
| 10/06/2023 | CMMB | Buy Now | Chemomab Therapeutics | $0.68 | 930.02% | Roth MKM | Dylan Dupuis | → $7 | Initiates | → Buy | Get Alert |
| 06/07/2023 | CMMB | Buy Now | Chemomab Therapeutics | $0.68 | — | Oppenheimer | Jeff Jones | — | Downgrade | Outperform → Perform | Get Alert |
| 04/18/2023 | CMMB | Buy Now | Chemomab Therapeutics | $0.68 | 930.02% | Oppenheimer | Jeff Jones | $12 → $7 | Maintains | Outperform | Get Alert |
| 03/10/2022 | CMMB | Buy Now | Chemomab Therapeutics | $0.68 | 2842.91% | Oppenheimer | Jeff Jones | $30 → $20 | Maintains | Outperform | Get Alert |
| 12/07/2021 | CMMB | Buy Now | Chemomab Therapeutics | $0.68 | 4314.36% | Aegis Capital | Nathan Weinstein | — | Initiates | → Buy | Get Alert |
| 05/26/2021 | CMMB | Buy Now | Chemomab Therapeutics | $0.68 | 6521.54% | Cantor Fitzgerald | Kristen Kluska | — | Initiates | → Overweight | Get Alert |
| 05/07/2021 | CMMB | Buy Now | Chemomab Therapeutics | $0.68 | 6080.11% | Oppenheimer | Jeff Jones | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Chemomab Therapeutics (CMMB)?
The latest price target for Chemomab Therapeutics (NASDAQ: CMMB) was reported by Oppenheimer on March 8, 2024. The analyst firm set a price target for $0.00 expecting CMMB to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Chemomab Therapeutics (CMMB)?
The latest analyst rating for Chemomab Therapeutics (NASDAQ: CMMB) was provided by Oppenheimer, and Chemomab Therapeutics maintained their perform rating.
When was the last upgrade for Chemomab Therapeutics (CMMB)?
There is no last upgrade for Chemomab Therapeutics.
When was the last downgrade for Chemomab Therapeutics (CMMB)?
The last downgrade for Chemomab Therapeutics Ltd happened on June 7, 2023 when Oppenheimer changed their price target from N/A to N/A for Chemomab Therapeutics Ltd.
When is the next analyst rating going to be posted or updated for Chemomab Therapeutics (CMMB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemomab Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemomab Therapeutics was filed on March 8, 2024 so you should expect the next rating to be made available sometime around March 8, 2025.
Is the Analyst Rating Chemomab Therapeutics (CMMB) correct?
While ratings are subjective and will change, the latest Chemomab Therapeutics (CMMB) rating was a maintained with a price target of $0.00 to $0.00. The current price Chemomab Therapeutics (CMMB) is trading at is $0.68, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.